2019
DOI: 10.1186/s12935-019-0778-1 View full text |Buy / Rent full text
Retracted 2019-12-30
|
|

Abstract: Background: Effective therapy for hepatocellular carcinoma (HCC) is currently an imperative issue, and sorafenib is a first-line drug for the treatment of HCC. However, the clinical benefit of sorafenib is often impaired by drug resistance. Accordingly, the present study was conducted to investigate the molecular mechanisms involving sorafenib resistance, with a focus on large tumor suppressor 2 (LATS2) and mitophagy.Methods: HepG2 liver cancer cells were treated with sorafenib and infected with adenovirus-loa… Show more

Help me understand this report
Editorial notices

Search citation statements

Order By: Relevance
Select...
0
6
0

Publication Types

Select...

Relationship

0
0

Authors

Journals